JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Evolution and current trends in the management of colorectal cancer liver metastasis

  • 0Graduate Medical Education, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Minerva Surgery +

|

July 2, 2024

|

July 2, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Metastatic colorectal cancer liver metastasis (CRLM) management is complex due to patient heterogeneity. A multidisciplinary team approach is crucial for personalized treatment and improved survival outcomes in CRLM.

Area Of Science

  • Oncology
  • Surgical Oncology
  • Gastroenterology

Background

  • Metastatic colorectal cancer (mCRC) significantly contributes to cancer-related mortality, with liver metastasis (CRLM) being most common.
  • Approximately 50% of colorectal cancer patients develop liver metastases, impacting overall survival rates.
  • Complete liver resection offers the best survival for resectable CRLM, but only 15-20% are candidates at diagnosis.

Purpose Of The Study

  • To highlight the complexity in evaluating treatment options for colorectal cancer liver metastasis (CRLM).
  • To emphasize the need for a multidisciplinary team approach in managing CRLM.
  • To discuss the evolution of CRLM management strategies.

Main Methods

  • Review of current treatment modalities for CRLM, including surgical resection, systemic therapies, and locoregional treatments.
  • Analysis of patient selection criteria for resection and the challenges posed by unresectable disease.
  • Discussion on the importance of a multidisciplinary team (MDT) in treatment planning.

Main Results

  • Complete liver resection provides up to 58% 5-year survival for resectable CRLM.
  • Median survival remains low for unresectable CRLM even with optimal chemotherapy.
  • Evolving management includes expanded resection criteria, targeted therapies, and advanced locoregional treatments.

Conclusions

  • Optimal management of CRLM is complex due to patient heterogeneity.
  • A multidisciplinary team is essential for defining resectability and personalizing treatment.
  • Personalized treatment strategies are vital from diagnosis through to completion of therapy for CRLM patients.

Related Concept Videos

Targeted Cancer Therapies 02:57

7.5K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Esophageal Varices-II: Clinical Features and Management 01:28

57

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

Metastasis 02:30

5.5K

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...